1. Home
  2. HAFC vs AVXL Comparison

HAFC vs AVXL Comparison

Compare HAFC & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hanmi Financial Corporation

HAFC

Hanmi Financial Corporation

HOLD

Current Price

$27.01

Market Cap

758.9M

Sector

Finance

ML Signal

HOLD

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$3.59

Market Cap

397.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAFC
AVXL
Founded
1982
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
758.9M
397.6M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
HAFC
AVXL
Price
$27.01
$3.59
Analyst Decision
Hold
Strong Buy
Analyst Count
3
3
Target Price
$28.50
$22.00
AVG Volume (30 Days)
365.6K
2.5M
Earning Date
01-27-2026
02-11-2026
Dividend Yield
3.96%
N/A
EPS Growth
15.36
N/A
EPS
2.40
N/A
Revenue
$246,352,000.00
N/A
Revenue This Year
$19.61
N/A
Revenue Next Year
$11.05
N/A
P/E Ratio
$11.35
N/A
Revenue Growth
5.84
N/A
52 Week Low
$19.25
$2.86
52 Week High
$29.46
$14.25

Technical Indicators

Market Signals
Indicator
HAFC
AVXL
Relative Strength Index (RSI) 36.16 34.54
Support Level $28.15 $3.56
Resistance Level $29.12 $3.82
Average True Range (ATR) 0.45 0.26
MACD -0.27 0.08
Stochastic Oscillator 3.19 2.97

Price Performance

Historical Comparison
HAFC
AVXL

About HAFC Hanmi Financial Corporation

Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Share on Social Networks: